SleepCharge by Nox Health Expands Cognitive Behavioral Therapy Program for Insomnia
October 06, 2020 08:00 ET
|
SleepCharge
ATLANTA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- SleepCharge by Nox Health has announced the next evolution of its program for Cognitive Behavioral Therapy for Insomnia (CBTi). The new program called...
Insomnia Awareness Night to Shed Light on Impact of Sleeplessness
June 15, 2020 08:05 ET
|
American Academy of Sleep Medicine
DARIEN, Ill., June 15, 2020 (GLOBE NEWSWIRE) -- June features the shortest nights of the year, but for those living with chronic insomnia, every night is long. That’s why the American Academy of...
Sleep Tech Devices Market value to cross $27 billion by 2025: Global Market Insights, Inc.
November 05, 2019 05:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Global Sleep Tech Devices Market is projected to surpass USD 27 billion by 2025, according to a new research report by Global Market...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
August 05, 2019 07:30 ET
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...
Dave Kenney Certified as a Brain Health Coach by Amen Clinics
July 16, 2019 08:00 ET
|
Emergo Recovery
BARRIE, Ontario, July 16, 2019 (GLOBE NEWSWIRE) -- Dave Kenney, Executive Director and CEO at Emergo Recovery, has been certified by Amen Clinics as a Brain Health Coach. The Brain Health Coaching...
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
June 24, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...
Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
June 23, 2019 17:30 ET
|
Minerva Neurosciences, Inc
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific...
Major New Digital CBT Study Links Better Sleep To Better Overall Health
September 25, 2018 11:00 ET
|
Big Health
SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Digital programs for improving sleep may improve overall health as well, according to new research published in JAMA Psychiatry. In a year-long...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
December 06, 2017 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing
August 25, 2017 09:30 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, Aug. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is...